Recently, the relationship between the kallikrein-kinin system and various types of hypertension in human (Margolius et al. 1971 (Margolius et al. , 1972b (Margolius et al. , 1974b Miyashita 1971; Seino et al. 1975 ) and experimental rats (Groxatto and San Martin 1970; Margolius et al. 1972a : Geller et al. 1972 Porcelli et al. 1975 Recent papers also described that a low sodium diet (Margolius et al . 1974a, b; Seino et; or administration of sodium-retaining steroids (Adetuyibi and Mills 1972; Geller et al. 1972; Marin-Grez et al. 1973; Margolius et al . 1974a , b) increased kallikrein excretion. There is a hypothesis that kallikrein excretion is related to the effective levels of circulating sodium retaining steroid and that alteration of aldosterone levels mediate changes in kallikrein excretion (Margolius et al. 1974b ).
The purpose of the present study is to elucidate the pathophysiological signifi cance and the influence of aldosterone antagonist (spironolactone) on urinary kallikrein excretion in low and normal renin subgroups of essential hypertension and in primary aldosteronism.
MATERIAL AND METHODS

Subjects
Studies were performed on 12 patients with essential hypertension , including 7 cases of l ow renin type (5 men and 2 women , 26-58 years old), 5 cases of normal renin type (5 men, 23-43 years old) and 6 patients with primary aldosteronism (one man and 5 women, 30-47 years old)
. The diagnosis of essential hypertension was established by a series of complete exmaination including history, physical exmainations , routine laboratory tests, intravenous pyelography, radioisotope renography, renoscintigraphy, renal arteriography, and determina tion of 11-OHCS, aldosterone , and urinary catecholamines or vanillyl mandelic acid.
The patients with primary aldosteronism , who were cured later by removal of adrenal adenoma, had persistent hypokalemia , suppressed plasma renin activity and i ncreased plasma aldosterone level .
Low renin and normal renin groups of essential hyperten sion were determined according to our criteria reported elsewhere (Abe et al . 1975) . Antihypertensive medications had b een discontinued at least two weeks before study .
These subjects were administered spironolactone (100 mg/day , oral administration) f or 7 days under sodium and potassium intak e of 200 mEq/day and 50-60 mEq/day, respectively. The diet had been started 5 days before th e initiation of the medication.T wenty four-hr urine samples were collected for measurement of kallikrein, sodium and potassium. Sampling of blood was done with f asting patients kept in recumbent position for at least one hr in the morning .
Method for the measurement of urinary kallik rein 
DISCUSSION
Sprionolactone is known as a specific aldosterone antagonist in the renal tubules (Vander et al. 1960 ). The previous observations indicated that aldosterone or other sodium-retaining steroid hormones increase kallikrein excretion in human and rat urine. On the other hand kallikrein excretion decreased after spironolactone treatment in a single subject with primary aldosteronism (Margolius et al. 1974b ). Further, Kaizu and Margolius (1975) .reported recently that kallikrein activity in suspensions of rat renal cortical cells could be increased by aldosterone and decreased by spironolactone. Now, one of the topics of hypertension research is on low renin essential hypertension. In patients with essential hypertension , about 20% have relatively low plasma renin activity and fail to increase it normally in response to sodium restriction and standing (Brunner et al. 1972; Crane et al . 1972 In low renin essential hypertension, two types of kallikrein excretion were observed. In one type (three cases), urinary kallikrein excretion decreased after spironolactone treatment. UNaV slightly increased and UKV decreased after the treatment. Plasma aldosterone before the spironolactone treatment showed high levels in this type. This suggests that spironolactone competes directly with the effect of aldosterone on the release of kallikrein at the renal tubules. In another type (4 cases), urinary kallikrein increased after the administration of spironolac tone. UNaV and UKV increased slightly. PRA increased and MBP fell significantly. In this type, plasma aldosterone level was normal. It could be thought that this fall of MBP and increase of PRA depend upon natriuresis caused by aldosterone antagonist as well as by increased kallikrein activity. Kinins are known as one of the most potent vasodilators; when infused in the renal artery kinins produce marked natriuresis (Webster and Gilmore 1964; Barraclough and Mills 1965; Stein et al. 1972 ). It may be thought that increased kallikrein after the spironolactone treatment in low renin essential hypertension produces kinin in the renal cortex, and these kinins are released to peritubular interstitial space or peritubular capillary circulation. The reason why kallikrein excretion was increased in the latter group of low renin patients in spite of the spironolactone administration is unknown. These investigations suggest that urinary kallikrein excretion is related to the effective levels of aldosterone at the renal distal tubules, and alterations of aldosterone levels at the tubules mediate the release of kallikrein . On the other hand, it may be that there is a different mechanism of sodium and kallikrein handling by the kidney in low renin essential hypertension as compared with normal renin essential hypertension and primary aldosteronism.
